MICROBIX BIOSYSTEMS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.33 CAD | 0.00% |
|
-1.49% | -15.38% |
| Apr. 25 | Microbix to Present New Lab Accreditation Program at European Congress on Clinical Microbiology | MT |
| Apr. 25 | Microbix Collaborator Introduces New Lab Accreditation Program | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 18.59M 25.44M | Sales 2025 * | 21.32M 29.18M | Capitalization | 33.19M 45.42M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 1.79 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.56 x |
| P/E ratio 2024 * |
16.5
x | P/E ratio 2025 * |
16.5
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on Microbix Biosystems Inc.
More press releases
| 1 week | -1.49% | ||
| Current month | -4.35% | ||
| 1 month | -7.04% | ||
| 3 months | -15.38% | ||
| 6 months | +40.43% | ||
| Current year | -15.38% |
1 week
0.33
0.35
1 month
0.320.36
Current year
0.320.45
1 year
0.230.47
3 years
0.230.87
5 years
0.170.87
10 years
0.160.90
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Groome
CEO | Chief Executive Officer | - | 12-03-07 |
James Currie
DFI | Director of Finance/CFO | - | 16-10-31 |
Mark Luscher
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Cochran
BRD | Director/Board Member | - | 90-09-30 |
Peter Blecher
BRD | Director/Board Member | - | 05-12-05 |
Cameron Groome
CEO | Chief Executive Officer | - | 12-03-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.33 | 0.00% | 700 |
| 24-05-09 | 0.33 | 0.00% | 53,786 |
| 24-05-08 | 0.33 | -4.35% | 59,786 |
| 24-05-07 | 0.345 | +1.47% | 14,786 |
| 24-05-06 | 0.34 | +1.49% | 12,000 |
Delayed Quote Toronto S.E., May 10, 2024 at 01:14 pm EDT
More quotes
Microbix Biosystems Inc. is a Canada-based life science company, which develops and commercializes biological and technological solutions for human health and wellbeing. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, mainly antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. It operates through two segments: the development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and the development and commercialization of products or technologies such as Kinlytic. Its Kinlyti urokinase is a biologic thrombolytic drug used to treat blood clots.
Calendar
2024-05-14
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.33
CAD
Average target price
0.8
CAD
Spread / Average Target
+142.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.38% | 33.19M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- MBX Stock